Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open Label Phase II Study of Tipifarnib in HRAS-Mutant Urothelial Carcinoma
KCT0004115Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tipifarnib in transitional cell carcinoma (TCC), sponsored by Samsung Medical Center. Started Oct 2015; status: completed.
02
Drugs
tipifarnib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on KCT0004115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004115.